PORTEC-4a:分子整合分型指导辅助治疗的成本效用分析
PORTEC-4a试验显示,分子整合风险分型指导(高)中危子宫内膜癌的个体化辅助治疗可达到相似的高局部肿瘤控制,且近半数患者免于辅助治疗。本成本效用分析纳入全部564例患者,分子分型组与标准阴道近距离放疗组QALYs相当,总医疗费用无显著差异,但分子分型策略在20000欧元/QALY阈值下具有89%的成本效益概率。
要点
- 分子整合分型指导的个体化辅助治疗在(高)中危子宫内膜癌中具有成本效益。
- 两臂QALYs相当,总医疗费用无显著差异,复发前费用分子分型组显著更低。
- 在20000欧元/QALY支付意愿阈值下,该策略成本效益概率为89%。
核心结论
- 基于分子整合分型的个体化辅助治疗对(高)中危子宫内膜癌患者比标准阴道近距离放疗更具成本效益,支持将该分型纳入常规临床实践。
研究设计与样本
- 国际、随机、3期PORTEC-4a试验的成本效用分析,纳入全部564例早期(高)中危子宫内膜癌患者,按2:1随机分为分子整合分型指导辅助治疗组(367例)和标准阴道近距离放疗组(197例),从医疗保健视角评估3年随访期内子宫内膜癌相关费用,使用EORTC-QLU-C10D量表计算质量调整生命年(QALYs),采用t检验比较,缺失数据多重插补。
主要发现
- 分子分型组与标准组QALYs相当(p=0.58)。
- 分子分型组总医疗费用略低于标准组但无统计学显著性(11898欧元 vs 13047欧元,p=0.11)。
- 复发前费用分子分型组显著低于标准组(9995欧元 vs 11926欧元,p<0.01)。
- 复发治疗费用两组无显著差异(1903欧元 vs 1121欧元,p=0.17)。
关键数值与推荐
- 在20000欧元/QALY的支付意愿阈值下,PORTEC-4a提出的策略具有成本效益的概率为89%。
临床怎么用
- 对于早期(高)中危子宫内膜癌患者,可考虑采用分子整合风险分型指导辅助治疗决策,以在维持肿瘤控制的同时节约医疗成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The international PORTEC-4a trial demonstrated that individualised adjuvant treatment for women with (high)intermediate risk endometrial cancer (HIR-EC), guided by a molecular-integrated-risk-profile, achieves similar high local tumour control, while nearly half of patients were spared adjuvant treatment. Although determination of the molecular-integrated-profile increases diagnostics costs due to additional immunohistochemistry and DNA-sequencing, these costs may be offset by savings on other care and improved patient outcomes. PATIENTS AND METHODS: Women with early-stage HIR-EC eligible for the PORTEC-4a trial, were randomised (2:1) to either adjuvant treatment according to their molecular-integrated-profile or standard vaginal brachytherapy (VBT). EC-related costs were evaluated from a healthcare perspective over a three-year follow-up period. Costs were related to quality-adjusted-life-years (QALYs) using the EORTC-QLU-C10D instrument. T-test compared mean QALYs and costs, with multiple imputation for missing data. RESULTS: All 564 patients were included in the cost-utility-analysis; 367 in molecular-profile arm and 197 in standard arm. QALYs were comparable (p = 0.58). Total healthcare costs were somewhat, but not significantly, lower in molecular-profile arm compared to standard arm (€11,898 vs €13,047, p = 0.11). Costs spent up until recurrence were significantly lower in molecular-profile arm (€9,995 vs €11,926, p < 0.01), while there was no significant difference in treatment for recurrence (€1,903 vs €1,121, p = 0.17). At a willingness-to-pay threshold of €20,000/QALY, the strategy as proposed by PORTEC-4a was 89% likely to be cost-effective. CONCLUSION: Individualised adjuvant treatment based on a molecular-integrated-profile was more cost-effective than standard VBT for patients with HIR-EC. These results further support the implementation of the molecular-integrated-profile in routine clinical practice.
引用
- van den Heerik ASVM, Horeweg N, Haverkort MAD, et al. Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trial. Radiother Oncol. 2026. PMID: 41621679. doi:10.1016/j.radonc.2026.111406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。